<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

AMG 706 - Motesanib diphosphate

產(chǎn)品貨號(hào)

Axon 1768 CAS [857876-30-3] MF C22H23N5O.2H3O4PMW 569.44 Purity: 99% Soluble in water Description A potent and orally bioavailable multiple receptor tyrosine kinase inhibitor, targeting VEGFR/PDGFR/c-KIT (IC50: 2, 3, 6, 84, 8 and 59 nm for VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT and Ret receptors respectively); potently inhibits angiogenesis and induces regression in tumor xenografts. References Certificates Categories Extra info A Polverino et al. AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis (...). Cancer Res. 2006, 66, 8715. ? A Coxon et al. Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clin. Cancer Res. 2009, 15, 110. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR PDGFR c-KIT RTK class III and IV; EC 2.7.10.1 Multiple receptor tyrosine kinase inhibitor Chemical name N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide bis(phosphate) Parent CAS No. [453562-69-1] Order Size Unit Price Stock 5 mg €105.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

AMG 706 - Motesanib diphosphate

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1768

CAS [857876-30-3]

MF C22H23N5O.2H3O4P
MW 569.44

Purity: 99%
Soluble in water

AMG 706

Description

A potent and orally bioavailable multiple receptor tyrosine kinase inhibitor, targeting VEGFR/PDGFR/c-KIT (IC50: 2, 3, 6, 84, 8 and 59 nm for VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT and Ret receptors respectively); potently inhibits angiogenesis and induces regression in tumor xenografts.

A Polverino et al. AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis (...). Cancer Res. 2006, 66, 8715.

A Coxon et al. Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clin. Cancer Res. 2009, 15, 110.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology VEGFR PDGFR c-KIT RTK class III and IV; EC 2.7.10.1

Multiple receptor tyrosine kinase inhibitor

Chemical name

N-(3,3-dimethylindolin-6-yl)-2-(pyridin-4-ylmethylamino)nicotinamide bis(phosphate)

Parent CAS No.

[453562-69-1]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>